Welcure Drugs & Pharmaceuticals Ltd has executed a Letter of Intent with Singapore-based Telexcell Trade PTE LTD for a proposed 25% equity investment at ₹20 per share, along with key board approvals, including a stock split, bonus issue, and capital raise initiatives.
Welcure Drugs announced that Telexcell Trade PTE LTD intends to acquire up to 25% stake in the company at ₹20 per share, a premium to its current market price. This strategic equity investment is planned as an all-cash deal and remains subject to due diligence, regulatory and shareholder approvals. The parties aim to finalise definitive agreements within 90 days.
The board approved a 1:10 bonus issue, granting 1 bonus share for every 10 shares held. Additionally, a stock split was cleared, converting each equity share of ₹10 into 10 equity shares of ₹1, subject to shareholder approval via postal ballot. These moves are aimed at improving liquidity and widening investor participation.
Read More: Equity Fund Inflows Rise 15% Annually, Sectoral and Flexi Cap Funds Lead the Surge!
Welcure recorded a sharp surge in revenue and profits in Q1FY26. Revenue jumped to ₹299.91 crore from ₹21.21 crore in Q4FY25, marking a 1,300% increase. Net profit soared 830% QoQ to ₹23.29 crore from ₹2.50 crore. The company’s performance was driven by its export-sourcing model, completing 7 assignments totalling ₹299.91 crore with fixed commissions and zero inventory risk.
Welcure plans to invest ₹70–80 crore in a cGMP-compliant agro pharma R&D lab and raise ₹80 crore via QIP. It has also secured a ₹517 crore mandate from Fortune Sagar Impex (Thailand), expected to generate ₹25.85 crore in service income during FY26. The company remains debt-free and is positioning itself for global botanical drug markets.
On September 4, 2025, Welcure Drugs & Pharmaceuticals share price opened at ₹9.68 on BSE, above the previous close of ₹9.22. The stock is trading at ₹9.68, hitting the upper circuit of 5%.
Welcure Drugs’ strategic LOI with Telexcell, along with robust financials, bonus issue, and stock split approvals, signal a transformative phase. With international expansion on the horizon and strong operational momentum, the company is aligning its structure for scalable growth and increased investor interest.
Disclaimer: This blog has been written exclusively for educational purposes. The securities or companies mentioned are only examples and not recommendations. This does not constitute a personal recommendation or investment advice. It does not aim to influence any individual or entity to make investment decisions. Recipients should conduct their own research and assessments to form an independent opinion about investment decisions.
Investments in securities are subject to market risks. Read all related documents carefully before investing.
Published on: Sep 4, 2025, 12:18 PM IST
Team Angel One
We're Live on WhatsApp! Join our channel for market insights & updates
Get the link to download the App
